367 reports of this reaction
1.3% of all ATAZANAVIR reports
#19 most reported adverse reaction
JAUNDICE is the #19 most commonly reported adverse reaction for ATAZANAVIR, manufactured by E.R. Squibb & Sons, L.L.C.. There are 367 FDA adverse event reports linking ATAZANAVIR to JAUNDICE. This represents approximately 1.3% of all 27,247 adverse event reports for this drug.
Patients taking ATAZANAVIR who experience jaundice should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
JAUNDICE is a less commonly reported adverse event for ATAZANAVIR, but still significant enough to appear in the safety profile.
In addition to jaundice, the following adverse reactions have been reported for ATAZANAVIR:
The following drugs have also been linked to jaundice in FDA adverse event reports:
JAUNDICE has been reported as an adverse event in 367 FDA reports for ATAZANAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
JAUNDICE accounts for approximately 1.3% of all adverse event reports for ATAZANAVIR, making it a notable side effect.
If you experience jaundice while taking ATAZANAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.